Patient Selection Challenges Persist Despite CT:VQ™ Advances
4DMedical’s CT:VQ™ technology has been clinically validated in a top respiratory journal, showing a leap in patient response rates for lung volume reduction surgery from 46% to 76%, promising improved outcomes and hospital efficiencies.
- Peer-reviewed study in leading respiratory journal
- CT:VQ™ improves LVRS patient response rate to 76%
- Non-invasive functional lung imaging from existing CT scans
- Enhances hospital economics by refining patient selection
- Findings presented at ATS 2026 Congress
Clinical Validation Elevates CT:VQ™ Impact
4DMedical Limited (ASX:4DX) has secured a significant clinical endorsement for its CT:VQ™ technology, with a peer-reviewed study published in the American Journal of Respiratory and Critical Care Medicine, the world’s foremost respiratory journal. The research demonstrates that CT:VQ™-guided selection can boost patient response rates to lung volume reduction surgery (LVRS) from the current 46% to a striking 76%, dramatically improving surgical outcomes.
This leap in efficacy stems from CT:VQ™’s ability to extract functional ventilation and perfusion data from standard non-contrast CT scans, sidestepping the need for additional imaging or contrast agents. Such integration promises to streamline pre-operative workflows and refine patient selection with greater precision.
Transforming LVRS Patient Selection and Hospital Economics
LVRS, a complex surgical intervention reserved for severe emphysema cases, demands precise patient selection to optimise outcomes and resource use. The study underlines how CT:VQ™ can reduce unnecessary invasive procedures by identifying patients most likely to benefit, thus concentrating surgical efforts where they matter most.
Hospitals stand to gain economically as well. LVRS programs generate revenue beyond the surgery itself, encompassing diagnostics, imaging, and inpatient care. However, margins are sensitive to patient outcomes, with poor selection leading to longer stays and complications. By enhancing selection accuracy, CT:VQ™ supports higher procedural success rates and better utilisation of specialised surgical infrastructure, improving contribution margins.
The company’s technology also aligns with the trend toward precision medicine, offering a non-invasive, data-rich tool that fits seamlessly into existing radiology workflows and can analyse historical scans to inform earlier clinical decisions.
Global Recognition at ATS 2026 Congress
The findings were presented at the American Thoracic Society International Conference 2026 in Orlando, the largest global forum for pulmonary medicine. This spotlight reinforces CT:VQ™’s growing stature among respiratory experts focused on advancing emphysema management through combined anatomical and functional lung assessment.
Interest in CT:VQ™ at ATS coincides with 4DMedical’s recent commercial momentum, including regulatory clearances and adoption at leading US academic medical centres, reflecting a technology gaining traction on both clinical and commercial fronts. For instance, the system’s deployment at top hospitals has surged alongside regulatory approvals in Europe and the UK, backed by substantial capital raises to fuel expansion expanded CT:VQ™ adoption and CE Mark certification.
Leadership and Future Engagements
The company will further discuss these advances in a live webinar featuring Dr Joseph Mammarappallil from Duke University School of Medicine, providing deeper insights into CT:VQ™’s clinical applications and future role in respiratory care.
Bottom Line?
CT:VQ™’s clinical validation sharpens 4DMedical’s edge in respiratory imaging, but its impact will hinge on adoption rates and integration into established surgical pathways.
Questions in the middle?
- How quickly will hospitals adopt CT:VQ™ for LVRS patient selection?
- What reimbursement changes might follow broader clinical validation?
- Can CT:VQ™ maintain its competitive lead amid evolving respiratory imaging technologies?
